NewAmsterdam Pharma Co. N.V. (NAMS), Wednesday announced positive data from Phase 3 TANDEM clinical trial, evaluating the fixed-dose combination of 10 mg Obicetrapib and 10 mg Ezetimibe.
The trial involved adult patients with heterozygous familial hypercholesterolemia and/or atherosclerotic cardiovascular disease or multiple ASCVD risk factors, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
The trial achieved all the co-primary points with the combination of Obicetrapib with Ezetimibe achieving an LS mean reduction of 48.6 percent compared to placebo at day 84.
The company expects the findings to support its regulatory filings globally.
Currently, NewAmsterdam's stock is falling 13.26 percent, to $20.15 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.